Equities Analysts Offer Predictions for VNDA FY2026 Earnings

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for Vanda Pharmaceuticals in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst O. Brayer anticipates that the biopharmaceutical company will post earnings per share of $0.07 for the year. Cantor Fitzgerald currently has a "Strong-Buy" rating on the stock. The consensus estimate for Vanda Pharmaceuticals' current full-year earnings is ($1.12) per share.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.05. Vanda Pharmaceuticals had a negative return on equity of 3.49% and a negative net margin of 9.51%. The firm had revenue of $50.04 million for the quarter, compared to the consensus estimate of $45.13 million.

Several other analysts also recently issued reports on the company. HC Wainwright reissued a "buy" rating and set a $20.00 target price on shares of Vanda Pharmaceuticals in a research note on Wednesday, May 7th. Wall Street Zen raised Vanda Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday.

Vanda Pharmaceuticals Trading Down 2.6%

VNDA traded down $0.12 on Wednesday, hitting $4.51. 361,867 shares of the company's stock traded hands, compared to its average volume of 638,746. The company's 50 day simple moving average is $4.32 and its 200-day simple moving average is $4.55. The firm has a market cap of $265.79 million, a price-to-earnings ratio of -14.09 and a beta of 0.66. Vanda Pharmaceuticals has a one year low of $3.81 and a one year high of $6.63.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. Quantinno Capital Management LP purchased a new position in shares of Vanda Pharmaceuticals in the 4th quarter worth approximately $48,000. PVG Asset Management Corp purchased a new position in shares of Vanda Pharmaceuticals in the 1st quarter worth approximately $48,000. Linden Thomas Advisory Services LLC purchased a new position in shares of Vanda Pharmaceuticals in the 1st quarter worth approximately $49,000. Nations Financial Group Inc. IA ADV purchased a new position in shares of Vanda Pharmaceuticals in the 1st quarter worth approximately $67,000. Finally, XTX Topco Ltd purchased a new position in shares of Vanda Pharmaceuticals in the 4th quarter worth approximately $69,000. Hedge funds and other institutional investors own 88.14% of the company's stock.

Insider Buying and Selling at Vanda Pharmaceuticals

In other news, CEO Mihael Hristos Polymeropoulos purchased 10,000 shares of the business's stock in a transaction on Wednesday, May 21st. The stock was acquired at an average price of $4.40 per share, for a total transaction of $44,000.00. Following the acquisition, the chief executive officer now directly owns 2,325,731 shares of the company's stock, valued at $10,233,216.40. This represents a 0.43% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 10.00% of the stock is currently owned by company insiders.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.